• Fennec Pharmaceuticals flagged four independent PEDMARK studies slated for presentation at the 2026 ASCO annual meeting.
• New evidence suggests PEDMARK can reduce cisplatin-related hearing loss across broader settings, with no signal of weakening cisplatin’s anti-cancer effect.
• Real-world reports indicate dosing about six hours post-cisplatin can fit routine oncology workflows, supporting potential expansion beyond current pediatric use.
• Pipeline includes an early-stage randomized trial design in metastatic germ cell tumors, extending PEDMARK evaluation into adult metastatic disease.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fennec Pharmaceuticals Inc. published the original content used to generate this news brief on June 10, 2026, and is solely responsible for the information contained therein.